NASDAQ · MURA
Mural Oncology PLC
$2.04 $0.00 (+0.00%) 1DKey Metrics
$36.38M
Market cap
—
P/E · TTM
—
Revenue · TTM
−$119.10M
Net income
EPS · TTM
$-6.90
Dividend yield
—
Free cash flow
−$118.45M
Beta · 1Y
—
EBITDA · TTM
−$119.63M
Gross margin
—
Snapshot
Market cap$36.38M
Enterprise value—
Shares outstanding17.3M
52-wk range$1.53 – $2.45
Avg volume · 20D799.9K
Net cash
—
Book value / share$3.20
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Mural Oncology PLC
IPO dateNov 3, 2023
Employees116
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
-74.7% · —
Financial Health
Current ratio5.90
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$51.63M
Cash Flow · TTM
Operating CF
−$118.41M
Capex
−$38.00K
Free cash flow
−$118.45M
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
0 / 9
Weak fundamentals · 0 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings